Arrowhead Pharma to pay $215 million for PRV in its latest acquisition
read at Endpoints ↗DealNeutral
Arrowhead Pharmaceuticals disclosed in an SEC filing that it will acquire PRV for $215 million, marking the highest price tag for a deal this year.
The purchase aligns with Arrowhead's strategy of expanding its pipeline through strategic acquisitions.
Separately, Twist Bioscience announced its intention to raise roughly $300 million via a public offering.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Arrowhead buys PRV for $215M; Twist hopes to raise $300M in public offering”
read at Endpoints ↗79 words · retrieved 22h ago
comments(0)
5-min edit window · permanent after that